Shows successful treatment of mucormycosis in COVID-19 patients, implying the need for early intervention and comprehensive care.
The poor and impaired immune functioning due to COVID infection along with unmonitored use of steroids, was the major cause of rise in mucormycosis. We now know that successful treatment of mucormycosis requires early diagnosis, reversal of underlying predisposing risk factors, surgical debridement and prolonged antifungal therapy.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: